High Flow Nasal Cannula Market

The high-flow nasal cannula (HFNC) market is projected to reach USD 1.44 billion by 2031 from USD 0.94 billion in 2026, at a CAGR of 8.9% during the forecast period.

The HFNC market is growing primarily due to the increasing prevalence of acute and chronic respiratory disorders, rising incidence of hypoxemic respiratory failure, and growing adoption of non-invasive respiratory support in hospitals and critical-care settings. HFNC provides heated and humidified oxygen at high flow rates with a more stable FiO2, while also reducing anatomical dead space, improving mucociliary clearance, decreasing work of breathing, and generating a mild positive airway pressure. These benefits, combined with better patient comfort and tolerance compared with tight-fitting non-invasive ventilation (NIV) masks, have encouraged its use in intensive care units, emergency departments, post-extubation care, neonatal and pediatric care, and perioperative settings. Another major growth driver is the expanding clinical application of HFNC beyond conventional acute respiratory failure. Increasing evidence and clinical experience support its use for pre- and post-intubation oxygenation, prevention of post-extubation respiratory failure, bronchoscopy, breaks from NIV/CPAP, and selected chronic respiratory conditions such as COPD. The ability of HFNC to provide effective oxygenation without an invasive airway, while allowing patients to communicate, eat, and drink, further supports its adoption.

To know about the assumptions considered for the study download the pdf brochure

Some of the leading companies currently participating in the high-flow nasal cannula market are Fisher & Paykel Healthcare Limited (New Zealand), Vapotherm (US), ResMed (US), Hamilton Medical AG (Switzerland), and Drägerwerk AG & Co. KGaA (Germany).

In the HFNC market, Fisher & Paykel Healthcare Limited (New Zealand) holds a leading position, supported by its extensive portfolio of HFNC systems, nasal cannulas, heated breathing circuits, and humidification solutions. The company’s Airvo and Optiflow platforms provide integrated solutions for neonatal, pediatric, and adult respiratory care, while its established global presence strengthens its competitive position. Vapotherm (US) is a key player in the HFNC market, driven by its specialized portfolio of high-flow respiratory support technologies, including the Precision Flow and HVT systems. Its focus on heated and humidified high-flow therapy and patient-specific interfaces supports adoption across acute-care and respiratory-care settings. ResMed (US) maintains a strong position through its broad respiratory-care portfolio and global distribution network, with high-flow therapy solutions and associated components complementing its established expertise in non-invasive respiratory support. Hamilton Medical AG (Switzerland) has a significant presence in the HFNC market through the integration of high-flow oxygen therapy (HFOT) capabilities into its critical-care ventilation platforms, supported by compatible nasal interfaces and breathing circuits. Drägerwerk AG & Co. KGaA (Germany) is another prominent participant, leveraging its established critical-care portfolio and Hi-Flow Star solutions, including high-flow therapy systems, humidification technologies, and patient interfaces. Its strong hospital presence and focus on advanced respiratory-care technologies further support its position in the HFNC market.

• In April 2026, Vapotherm received FDA 510(k) clearance for its All Patient Circuit, enabling the HVT 2.0 high-velocity therapy system to provide therapy across 2–45 L/min using a single disposable circuit, including neonatal and infant settings.
• In February 2025, Hamilton Medical announced that the HAMILTON-HF90, its standalone high-flow oxygen therapy device, became available in all CE markets. The system is designed for high-flow oxygen therapy across emergency, intermediate-care and ICU environments and supports mobility/transport within healthcare facilities.

Fisher & Paykel Healthcare Limited (New Zealand)

Fisher & Paykel Healthcare is a New Zealand-based medical technology company focused on the development, manufacturing, and commercialization of healthcare products for respiratory care, acute care, surgery, and obstructive sleep apnea. The company offers a broad portfolio of respiratory care solutions, including high-flow nasal therapy systems, humidification systems, breathing circuits, nasal cannulas, masks, and related consumables. Fisher & Paykel Healthcare is particularly well established in the HFNC market through its F&P Airvo systems and Optiflow nasal high-flow therapy, which are designed to deliver heated and humidified respiratory gases to patients across different clinical settings. The company focuses strongly on product innovation and respiratory care technologies, making it a key player in the global high-flow nasal cannula market.

Vapotherm (US)

Vapotherm is a medical technology company focused on non-invasive respiratory support, with a particular emphasis on High Velocity Therapy (HVT), a form of heated, humidified high-flow respiratory support delivered through a nasal interface. Its HFNC-related portfolio includes the Precision Flow Hi-VNI system, HVT 2.0, ProSoft nasal cannulas, disposable patient circuits, and other accessories. The company’s systems are designed for respiratory distress across neonatal, pediatric, and adult populations and are used in acute-care environments such as emergency departments, critical care, and respiratory care. Vapotherm has established a global presence, with its technology used in more than 2,400 hospitals and distributed across more than 40 countries.

Market Ranking:

In the HFNC market, Fisher & Paykel Healthcare Limited (New Zealand) is recognized as the market leader, supported by its comprehensive portfolio of dedicated HFNC systems, nasal interfaces, heated breathing circuits, and humidification solutions. The company’s Airvo and Optiflow product platforms, strong global distribution network, and extensive presence in respiratory care have established a strong competitive position in HFNC. Vapotherm (US) holds a leading position in the market, driven by its specialized high-flow respiratory therapy portfolio, including the Precision Flow and HVT platforms, and its focus on delivering heated and humidified respiratory support across adult, pediatric, and neonatal populations. ResMed (US) ranks among the prominent players, supported by its broad respiratory-care portfolio, global commercial presence, and increasing focus on high-flow therapy solutions and associated components. Hamilton Medical AG (Switzerland) has established a strong position through its integration of HFNC/HFOT capabilities into its advanced critical-care ventilation portfolio, including dedicated high-flow solutions and compatible nasal interfaces and breathing circuits. Drägerwerk AG & Co. KGaA (Germany) is another major participant, leveraging its extensive critical-care and respiratory-care portfolio, including high-flow oxygen therapy solutions, humidification systems, and patient interfaces. Its strong presence across hospitals and intensive care units, combined with continuous innovation in respiratory support technologies, strengthens its position in the global HFNC market.

Related Reports:

High Flow Nasal Cannula Market by Product (Systems, Consumables & Accessories (Humidifiers, Interfaces)), Patient Type (Neonatal & Pediatric), Application (Acute Respiratory Failure, COPD), End User (Hospitals), & Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]